Jiaju Lyu

机构：Shandong Provincial Hospital, Shandong First Medical University · ORCID：0000-0002-7123-8652

发表论文 28 篇 · 总被引 76 次 · h-index 5

代表论文

• Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial (2024 · Nature Cancer · 被引 23)
• Integrative exploration of the mutual gene signatures and immune microenvironment between benign prostate hyperplasia and castration-resistant prostate cancer (2023 · The Aging Male · 被引 10)
• Interim results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy for patients with cT2-T4aN0M0 MIBC. (2022 · Journal of Clinical Oncology · 被引 9)
• Hypoxia activates the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in a prostatic stromal cell line: A mechanism for the pathogenesis of benign prostatic hyperplasia (2023 · Current Urology · 被引 6)
• Immune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder carcinoma: A narrative review (2024 · Current Urology · 被引 5)
• Construction and evaluation of a novel prognostic risk model of aging-related genes in bladder cancer (2023 · Current Urology · 被引 5)